首页> 美国卫生研究院文献>OncoTargets and therapy >Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review
【2h】

Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review

机译:恶性心包积液对晚期肺癌患者心包内贝伐单抗的持续反应:一例病例并文献复习

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Malignant pericardial effusion (MPCE) is a common complication of advanced malignant tumors, and interferes severely with patient prognosis and quality of life. The standard treatment for this complication is intracavitary perfusion of chemotherapeutic drugs, which is limited by unsatisfactory therapeutic effects and serious adverse events. We report a patient with MPCE who was treated with bevacizumab by pericardial perfusion, resulting in a complete response. This case supports the use of intrapericardial bevacizumab as a potential treatment for MPCE.
机译:恶性心包积液(MPCE)是晚期恶性肿瘤的常见并发症,严重干扰患者的预后和生活质量。这种并发症的标准治疗方法是腔内灌注化疗药物,这受到治疗效果不理想和严重不良事件的限制。我们报告了一名心包灌注患者使用贝伐单抗治疗的MPCE患者,获得了完全缓解。该病例支持使用心包内贝伐单抗作为MPCE的潜在治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号